|
Lymphoproliferative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fifteen patients with an established diagnosis of cutaneous lymphoma were prospectively recruited and seen in the university multidisciplinary cutaneous lymphoma program with MF, an MF- variant, CD30-positive lymphoproliferative disorder, or cutaneous B-cell lymphomas and were included in our study.
|
29318585 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The most frequent CTCL subtypes, in decreasing order of prevalence, were mycosis fungoides (MF), including its variants (75.7%); CD30+ primary cutaneous lymphoproliferative disorders (7.2%); and Sézary syndrome (SS) (3.1%).
|
30294921 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
These were considered in four main categories: primary cutaneous B cell lymphomas (12 cases), primary cutaneous T cell lymphomas/lymphoproliferations with CD8+/cytotoxic phenotype (12 cases), primary cutaneous CD30-positive lymphoproliferative disorders (15 cases) and primary cutaneous T cell lymphomas/leukaemias with CD4+ phenotype (4 cases).
|
31781845 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Prospective, nonblinded survey design utilizing questionnaires including panels of QoL indices obtained from 105 patients with mycosis fungoides, Sezary syndrome, and CD30+ lymphoproliferative disorder.
|
30074622 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Detection of clonal rearrangement of T-cell receptor genes in the diagnosis of primary cutaneous CD30 lymphoproliferative disorders.
|
17083688 |
2006 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Non-MF/SS PCLs were primarily of T-cell origin (61%) where CD30+ lymphoproliferative disorders predominated, followed by Epstein-Barr virus-induced lymphomas, and peripheral T-cell lymphomas, not otherwise specified.
|
28400635 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomatoid papulosis (LyP) belongs to the spectrum of primary cutaneous CD30-positive lymphoproliferative disorders.
|
23026936 |
2013 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Seven of 12 (58%) cutaneous CD30-positive lymphoproliferative disorders were also ZAP-70-positive.
|
15133473 |
2004 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD8-positive, CD30-positive cutaneous lymphoproliferative disorders constitute a rare subset of T-cell lymphoproliferative conditions, including variants of primary cutaneous anaplastic large cell lymphoma (ALCL), mycosis fungoides, lymphomatoid papulosis type D, cutaneous gamma-delta T-cell lymphoma and cutaneous peripheral T-cell lymphoma.
|
28497585 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas none of the patients in our index series exhibited EBV positivity, here we discuss a very unique example of a 14-year-old girl diagnosed with EBV positive CD30 positive lymphoproliferative disorder strongly resembling the cases of intra-oral type C lymphomatoid papulosis.
|
30292067 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Mycosis fungoides (MF) is the most common primary cutaneous T-cell lymphoma (CTCL), followed by CD30+ lymphoproliferative disorders, including lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL).
|
26266670 |
2016 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Another photoresponsive CTCL variant is lymphomatoid papulosis (LP), a CD30+ lymphoproliferative disease characterised by chronically recurring papules.
|
30325389 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Primary cutaneous CD8+ and CD30+ T-cell lymphoproliferative disorders: case reports and clinical implications.
|
30670369 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a diagnosis of lymphoma is established, it is important to exclude systemic anaplastic lymphoma kinase-negative ALCL involving the breast, primary cutaneous ALCL, and other CD30(+) lymphoproliferative disorders.
|
24878027 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases.
|
31355940 |
2020 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder.
|
28860025 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, we aimed to analyze the expression of 5-hmC in cutaneous CD30-positive lymphoproliferative disorders and compare it with a control group composed of reactive infectious and inflammatory disorders with CD30-positive cells.
|
25353265 |
2014 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The current clinicopathologic classification of CD30+ cutaneous lymphoproliferative disorders is insufficient.
|
17387297 |
2007 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ lymphoproliferative disorders (LD) represent a spectrum of entities ranging from self-limited proliferations or cutaneous lesions with favorable prognosis, such as lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma (ALCL), to more aggressive malignancies such as systemic ALK-positive and ALK-negative ALCL.
|
31705818 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Sinusoidal CD30+ diffuse large B-cell lymphoma can masquerade as anaplastic large cell lymphoma in pediatric posttransplant lymphoproliferative disorders.
|
28035754 |
2017 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In order of frequency, diagnoses were: mycosis fungoides (40.5%), peripheral T-cell lymphoma not otherwise specified (22.95%), adult T-cell lymphoma/leukemia (18.9%), CD30+ lymphoproliferative disorders (6.8%), hydroa vacciniforme-like lymphoma (5.4%), extranodal NK/T-cell lymphoma (4.1%) and Sézary syndrome (1.4%).
|
29166501 |
2018 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Clinicopathologic and microenvironmental analysis of primary cutaneous CD30-positive lymphoproliferative disorders: a 26 year experience from an academic medical center in Brazil.
|
31640798 |
2019 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, primary cutaneous CD30+ lymphoproliferative disorders form a heterogeneous spectrum including anaplastic large cell lymphomas, the majority of which display a good prognosis.
|
10955685 |
2000 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
CD30+ cutaneous lymphoproliferative disorders include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
|
16412208 |
2006 |
|
Lymphoproliferative Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
It represents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP), which currently has no approved treatment.
|
28980004 |
2017 |